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Abstract
Background. Infection of pancreatic necrosis is the most dangerous complication of acute necrotizing pancreatitis. Infection
is undoubtedly caused by the endogenous flora of the host. This is why prophylaxis with a broad-spectrum antibiotic is
considered an effective procedure. However, two aspects should be taken into consideration when choosing the antibiotic; it
should have the spectrum of action consistent with the pathogens and it should penetrate effectively to the necrotic tissue of
the pancreas. The aim of the study was to estimate the efficacy of piperacillin/tazobactam penetration into pancreatic
necrosis in patients who received intravenous infusion of piperacillin/tazobactam at a dose of 4.5 g every 8 h for 14/21 days,
as the prophylaxis in the treatment of acute necrotizing pancreatitis. Patients and methods. Necrotic tissue of the pancreas
and the inflammatory ascites surrounding the pancreas were derived from 15 patients (male, 10; female, 5; mean age 46
years), who underwent laparatomy due to pancreatic necrosis after treatment for 14/21 days. Tissue/fluid samples were
investigated for the concentration of the antibiotic by fluoroscopic/spectroscopic methods of registration in an HPLC
system. Results. The mean concentration of piperacillin/tazobactam was established as 120 mg/kg (SD9/34) in the necrotic
pancreatic tissue and as 183 mg/kg (SD9/37) in the inflammatory pancreatic ascites. Conclusions. In patients with acute
necrotizing pancreatitis, the study indicates effective penetration of piperacillin/tazobactam to the necrotic pancreatic tissue
and to the inflammatory ascites surrounding the pancreas.
Key Words: Acute necrotizing pancreatitis, antibiotic prophylaxis, piperacillin/tazobactam, antibiotic penetration of
pancreatic necrosis
Introduction
Infection of pancreatic necrosis is rightly considered a
life-threatening complication in patients with acute
necrotizing pancreatitis [1,2]. Many reports indicate
that treatment with a broad-spectrum antibiotic, if
applied at the initial stage of disease, is potent to
counteract the endogenous infection of the necrosis
and consequently improves the results of treatment.
However, two aspects should be taken into considera-
tion when choosing the antibiotic; it should have the
spectrum of action consistent with the pathogens and
it should penetrate effectively to the necrotic tissue of
the pancreas [3/6]. Piperacillin/tazobactam is a well
known broad-spectrum antibiotic, in general use, with
a spectrum of action consistent with most of the
pathogens responsible for endogenous infection. It is
indicated for most mixed hospital infections, serious
intra-abdominal infections and sepsis, including in-
fection of pancreatic necrosis [5,7/10]. The aim of
the study was to estimate the efficacy of piperacillin/
tazobactam penetration into pancreatic necrosis in
patients who received intravenous infusion of piper-
acillin/tazobactam at a dose of 4.5 g every 8 h for
14/21 days, as prophylaxis in the treatment of acute
necrotizing pancreatitis.
Patients and methods
There were 15 patients (male, 10; female, 5; mean
age 46 years) with acute necrotizing pancreatitis
treated at the department from 2000 to 2004. The
criteria for including them in the study were estab-
lished as follows: age over 18 years, pancreatic necrosis
confirmed by USG/CT scanning, hospitalization not
later than 72 h after the onset of disease, no antibiotic
treatment in the 7 days prior to the symptoms of
pancreatitis, level of C-reactive protein /120 mg/l at
the time of hospitalization, patient’s consent for
investigation. Patients who did not comply with all
points of the cited criteria were excluded from the
evaluation.
The diagnosis of pancreatic necrosis was estab-
lished by clinical and biochemical evaluation. All
patients presented on admittance with serious ab-
dominal pain, vomiting, dehydration and oliguria, as
well as circulatory and respiratory disorders such as
tachycardia, low blood pressure, tachypnoea. There
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was inflammatory tumour palpable in the upper
abdomen and regional peritonitis was also present in
all of them. Increased white cell count, increased level
of blood/urine amylase, and C-reactive protein
/120 mg/l complemented the serious clinical status
of each patient. The diagnosis was confirmed in every
case by USG and spiral CT scanning. In patient nos
3, 7, 8, 11, 12 and 13, spiral CT indicated inflam-
matory process of pancreatic gland with necrosis of
/30% but B/50% of the parenchyma. In patient nos
1, 2, 4, 5, 6, 9, 10, 14 and 15, spiral CT indicated
inflammation of the pancreatic gland with necrosis of
/50% of the parenchyma. Inflammatory ascites
surrounding the pancreas was also present. The
APACHE II scores amounted to at least 10 points in
all patients and the Ranson score oscillated between 4
and 8 points, as established during 24 h after
admittance (Table I).
The treatment started immediately after admission
and consisted of general and intensive care, TPN
and intravenous infusion of piperacillin/tazobactam at
a dose of 4.5 g infused over 30 min every 8 h.
In patient nos 1, 3, 4, 6, 9, 10, 11 and 13 antibiotic
infusion started before or simultaneously with the
intravenous fluid resuscitation. In patient nos 2, 5,
7, 8, 12, 14 and 15 antibiotic infusion started after
adequate fluid resuscitation. Intravenous infusion
of the antibiotic was maintained up to 14/21 days
of treatment / the day when the patients underwent
operation.
Surgical intervention was undertaken due to ex-
tended pancreatic necrosis. Deteriorating patient’s
status, growing intra-abdominal pressure (B/20 cm
H2O) and increasing toxaemia, as well as palpable
mass and symptoms of regional peritonitis in
the upper part of abdomen were the indications
for the operation. The decision was supported by
CT scanning indicating changes of the dense pan-
creatic inflammatory parenchyma into the liquid
suppurative collection. Symptoms of infection before
the operation were only evident in patient nos 5
and 10.
Blood plasma concentration of piperacillin/tazobac-
tam was evaluated in each patient while receiving
three consecutive doses of the antibiotic at 1/2 days
before the operation. Blood samples were collected
at the following sampling time points: T /0.5, i.e.
30 min after the dose infusion was completed; T
/2, i.e. 2 h after the dose infusion was completed.
Blood samples were centrifuged, separated and frozen
at /808C until the time of analysis in an HPLC
system.
The operation comprised laparatomy, necrosect-
omy, peritoneal lavage and postoperative drainage.
Shreds of the necrotic pancreatic tissue and the
inflammatory ascites from omental bursa were col-
lected for bacteriology, as well as for spectroscopic
evaluation of antibiotic concentration. The spectro-
scopic procedure required approximately 1 g of
necrotic pancreatic tissue and 1 ml of the ascites
surrounding the pancreas. The samples were frozen at
/808C until the time of analysis by fluoroscopic/
spectroscopic methods of registration in an HPLC
system. The spectrometer was supplied with two
independent monochromatic inductors and registra-
tion, xenon lamp and luminescence signal detector
PMT with a spectrum range of 210/370 nm. The
results were evaluated statistically.
Results
On day 1/2 before the operation the mean blood
plasma concentration of piperacillin/tazobactam in
the 15 patients reached the level of 234 (SD9/11) to
240 (SD9/12) mg/l at 30 min after the dose infusion
and 61 (SD9/7) to 64 (SD9/7) mg/l at 2 h after the
infusion (Figure 1).
Table I. The amount of pancreatic necrosis calculated by the initial spiral CTand the Ranson score calculated at 24 h after admittance in 15
patients with necrotizing pancreatitis.
No. Initials Age Sex Amount of necrosis (%) Ranson score
1* J. Ch. 54 M B/50 6 pts
2 K. L. 30 M B/50 6 pts
3* D.T. 28 F /30 but B/50 4 pts
4* A. R. 48 M B/50 5 pts
5 T. D. 56 M B/50 7 pts
6* K. P. 32 M B/50 6 pts
7 G. S. 49 M /30 but B/50 4 pts
8 T. C. 52 F /30 but B/50 4 pts
9* B.K. 64 F B/50 5 pts
10* L. P. 49 M B/50 8 pts
11* B. J. 72 F /30 but B/50 4 pts
12 R. T. 47 M /30 but B/50 4 pts
13* H. M. 38 F /30 but B/50 4 pts
14 W. C. 42 M B/50 5 pts
15 E. S. 51 M B/50 6 pts
*Patients receiving antibiotic before or simultaneously with fluid resuscitation.
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Bacteriological examination of the necrotic tissue
samples collected during the operation indicated
aseptic necrosis in all patients except patient nos 5
and 10, in whom infection with Enterococcus fae-
cium and methicillin-resistant Staphyloccoccus aureus
(MRSA) was recognized, respectively (Table II).
The concentration of piperacillin/tazobactam dif-
fered from 67 mg/kg to 102 mg/kg in the necrotic
pancreatic tissue and from 101 mg/kg to 190 mg/kg in
the ascites surrounding the pancreas in patients who
received antibiotic after sufficient fluid resuscitation.
The concentration of piperacillin/tazobactam was
higher in patients receiving antibiotic before or
simultaneously with the fluid resuscitation and dif-
fered from 102 mg/kg to 176 mg/kg in the necrotic
pancreatic tissue and from 190 mg/kg to 261 mg/kg in
the ascites surrounding the pancreas. The differences
in the concentration of piperacillin/tazobactam in the
necrotic pancreatic tissue and in the ascites surround-
ing the pancreas between these two groups were
significant (pB/0.01).
The mean concentration of piperacillin/tazobactam
in the necrotic tissue of pancreas was established at
120 mg/kg (SD9/34) and in the ascites surrounding
the pancreas at 183 mg/kg (SD9/37).
The results are indicated in Table III / patients
receiving antibiotic before or simultaneously with the
fluid resuscitation are indicated with an asterisk.
Discussion
The study indicates that intravenous infusion of
piperacillin/tazobactam at a dose of 3/4.5 g per
24 h, administered to the patient at the initial stage of
acute necrotizing pancreatitis, allowed the antibiotic
to reach high and effective concentrations in the
necrotic pancreatic tissue and in the inflammatory
ascites surrounding the pancreas. Experimental stu-
dies in rats, as well as pharmacodynamic studies
performed on healthy pancreas, indicate sufficient
penetration of piperacillin/tazobactam to the pancrea-
tic parenchyma [4,6,10/13]. This opinion is distinctly
supported by Bassi and his co-workers, who con-
cluded that the antibiotics which proved capable of
penetrating into the pancreas in physiological condi-
tions maintained this ability in the course of acute
disease with a necrotic component. Their use in the
prophylaxis of necrotizing pancreatitis appears useful
[14]. So, it was a challenge to prove whether the
antibiotic could reach high (i.e. therapeutic) concen-
trations in the necrotic pancreatic tissue in clinical
conditions, in patients with advanced hypovolaemia
and pancreatic toxaemia. The data achieved in the
present study fulfilled the expectations.
Antibiotic prophylaxis has been shown in many
reports as the therapeutic modality able to improve
the results of treatment and to increase chances of the
patient for a positive outcome in acute necrotizing
pancreatitis [7,8,11,15,16]. Despite the adequate
fluid resuscitation, effective intensive care and total
parenteral nutrition, antibiotic prophylaxis became
the gold standard of the inceptive therapy for serious
pancreatic necrosis. Opponents of this approach
do not see the advantages of antibiotic prophylaxis,
as shown by Isenmann in his latest double-blind,
placebo-controlled study with ciprofloxacin/metroni-
dazole [17].
The policy of the inceptive antibiotic therapy is
obvious / to keep necrosis sterile for as long as
possible [1,3,7,8]. Infection of the necrosis is usually
initiated by the endogenous pathogens of the host,
mainly by enterococci and bacilliform Gram-negative
bacteria from the alimentary tract [18,19]. Two
aspects should be taken into consideration when
choosing the antibiotic; it should have the spectrum
of action consistent with the pathogens and it should
penetrate effectively to the necrotic tissue of the
pancreas.
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Figure 1. Blood serum concentrations of piperacillin/tazobactam in
15 patients with necrotizing pancreatitis while receiving 3 con-
secutive doses of the antibiotic at 1/2 days before the operation.
Concentrations were measured from blood samples collected at the
following time points: T/0.5, 30 min after the antibiotic infusion;
T/2, 2 h after the antibiotic infusion. Mean values for T/0.5/
234 mg/l (SD9/11) to 240 mg/l (SD9/12); T/2/61 mg/l (SD9/7)
to 64 mg/l (SD9/7).
Table II. Bacteriological evaluation of the necrotic pancreatic tissue samples collected during the operation in 15 patients.
No. 1* 2 3* 4 5 6* 7 8 9* 10 11* 12 13* 14 15
Result / / / / E / / / / S / / / / /
/, aseptic; E, Enterococcus faecium ; S, Staphylococcus aureus (MRSA).
*Patients receiving antibiotic before or simultaneously with fluid resuscitation.
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The systemic use of imipenem-cilastatinum, mer-
openem, fluoroquinolones and metronidazole is cur-
rently recommended for the management of
pancreatic endogenous infection [1,3,10,13]. All in-
dicated agents have a suitable spectrum of action and
seem to penetrate well to the pancreatic juice and
pancreatic parenchyma. Studies have indicated that
meropenem, cefepim and imipenem are potent en-
ough to reach high concentrations in the tissue of the
pancreatic gland [6,16,20]. High concentrations of
meropenem and cefepin in pancreatic parenchyma
were also observed by Saglamakaya in rat experimen-
tal pancreatitis [10]. However, some of these studies
were performed on pancreas unchanged by the
inflammatory process.
On the other hand, the infection of pancreatic
necrosis could develop despite the fact that the
antibiotic spectrum is suitable for the pathogens
responsible for the infection, as shown by the study
with meropenem and imipenem, and by many other
clinical observations [6,9,10,12,15,21,22]. The rate
of necrotic area in the pancreas corresponds statisti-
cally with the rate of inflammatory complications
in the patient. In patients with necrosis exceeding
/50% of the pancreas, as evaluated on the Baltazar
scale by spiral CT, infection is the rule [22]. Perez and
his co-workers argue for such a correlation and Bassi
et al. [15] indicate that the concentration of imipenem
in the pancreatic necrotic tissue does not very often
exceed the minimal inhibitory concentration (MIC)
that could be pernicious for the endogenous bacteria
[7,15,17]. This is presumably due to poor penetration
of the antibiotic to necrotic tissue, so the MIC of the
antibiotic could not effectively prevent the infection of
the expansive necrosis. The failure of the antibiotic
action could be also influenced by the patient’s
hypovolaemia, the general level of toxicity and the
time evolved from the onset of disease. The effective-
ness of antibiotic penetration to the area of pancreatic
necrosis could be increased by changes in dosage
schedules and by the use of multiple doses, as well as
by using more effective ways of administration. The
intravenous route appears to be more effective than
the intramuscular route, especially in the repeated
infusion regimen of administration [5,14,15].
Piperacillin/tazobactam is a very well known broad-
spectrum antibiotic indicated for most mixed hospital
infections, serious intra-abdominal infections and
sepsis, including infection of pancreatic necrosis. It
has a spectrum of action consistent with most of the
pathogens responsible for endogenous infection of
pancreatic necrosis. The evaluation of piperacillin/
tazobactam concentration by fluoroscopic/spectro-
scopic methods in patients with pancreatic necrosis
presented in this study shows that the antibiotic is
potent enough to reach levels as high as 176 mg/kg
in necrotic tissue and 261 mg/kg in ascites surround-
ing the pancreas. The tissue/ascites concentration
levels of the antibiotic were almost as high as theT
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concentration levels established in the patient’s blood
plasma during the infusion of three consecutive doses
at 1/2 days before the operation. These values
exceeded three- to five-fold the usual concentration
of the antibiotic indicated for pancreatic parenchyma
as therapeutic. The rate of antibiotic concentration
was significantly higher in patients receiving the
antibiotic before or simultaneously with the fluid
resuscitation (pB/0.01). It seems to be a little curious
but it could not be explained at that stage of the study.
Bacteriological examination of the tissue samples
collected at the time of operation indicated the
effective antimicrobial activity of the antibiotic. In
all patients bacteriological seeds were negative, except
for patients 5 and patient 10, in whom infection with
E. faecium and MRSA was recognized, respectively.
Of course, these two bacteria are resistant to piper-
acillin/tazobactam. Patient nos 5 and 10 developed
infected necrosis and undoubtedly required opera-
tion. Why then, were the patients who remained
aseptic operated upon? It must be emphasized
that surgical intervention was undertaken in these
patients because of deteriorating general status due to
growing intra-abdominal pressure (B/20 cm H2O)
and increasing toxaemia. CT scans indicated changes
in the dense pancreatic inflammatory parenchyma
into a liquid suppurative collection corresponding
with the palpable mass and symptoms of regional
peritonitis in the upper part of abdomen. The
increasing risk of multiple organ failure forejudged
the decision, although there were no evident symp-
toms of infection.
As shown in a previous clinical study that was
conducted from 1999 to 2003 in the Department of
General, Transplantation and Liver Surgery, Medical
University of Warsaw, prophylactic use of piperacillin/
tazobactam in our patients significantly increased the
rate of aseptic necrosis and significantly reduced the
rates of inflammatory complications and mortality.
Thus, the antibiotic prophylaxis with piperacillin/
tazobactam appeared to be beneficial for our patients
from a clinical point of view [23,24]. In contrast,
some other studies do not confirm these effects. In the
latest double-blind, placebo-controlled study with
ciprofloxacin and metronidazole, Insenmann and his
co-workers found no benefits from the antibiotic
prophylaxis. They included 114 patients in the inten-
tion-to-treat analysis. Patients were recruited on the
basis of an elevated serum CRP in combination with
pancreatic necrosis on CT. In patients with necrotiz-
ing pancreatitis, no differences between the verum
and the placebo group were observed [17].
The results of this study add fuel to the discussion
as to whether prophylactic antibiotic therapy in
patients with acute necrotizing pancreatitis is a
beneficial approach. Unfortunately, neither the data
presented in this paper nor our previous experiences
allow us to draw firm conclusions.
Despite the substantial doubts as to the effective-
ness of antibiotic prophylaxis in the treatment of acute
necrotizing pancreatitis, it remains acceptable and in
general use as a modality of inceptive therapy. In most
of the published studies, meropenem or imipenem is
widely recommended. Our study shows that although
the spectrum of action of piperacillin/tazobactam is
not as broad as the spectrum of meropenem, imipe-
nem-cilastatinum and fluoroquinolones, it could be of
greater clinical value. Piperacillin/tazobactam shows
extremely good penetration into pancreatic necrosis,
it is cost-effective and does not increase problems
with antibiotic resistance and fungal infection. Such
requirements could not be fulfilled by imipenem-
cilastatinum and meropenem or by fluoroquinolones
[1,6,12,10,13].
Conclusions
In patients with acute necrotizing pancreatitis treated
with intravenous infusion of piperacillin/tazobactam,
concentrations of the antibiotic reached effective,
therapeutic levels in the necrotic pancreatic tissue
and in the inflammatory ascites surrounding the
pancreas.
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